EMPOWER: Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (clinicaltrials.gov) - Sep 5, 2026 - P4 | N=113 | Recruiting | Sponsor: University Hospital, Basel, Switzerland | N=172 ➔ 113 | Trial completion date: Feb 2027 ➔ Sep 2026 | Trial primary completion date: Jan 2027 ➔ Sep 2026
Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hepatology • Liver Failure • Renal Disease
|